# name
Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease

# metadata.dc.description.abstract[].value
Parkinson's disease (PD) is a progressive, neurodegenerative disorder that affects ~1% of individuals over the age of 60, which turns to 5% in subjects up to 85 years (de Lau and Breteler, 2006). On the other hand, a form of PD, called early-onset PD (EOPD), arises at an earlier age (<45; Bonifati et al., 2005; Ylikotila et al., 2015). EOPD patients generally display a slower progression of the disease and present a better response to dopaminergic treatments; however, they may finally develop a full PD symptomatology (i.e., bradykinesia, resting tremor, muscular rigidity and postural instability, drug-induced dyskinesia; Olgiati et al., 2016).

# metadata.dc.relation.ispartof[].value
Frontiers in Neuroscience, 2017, vol. 11, num. 652

# metadata.dc.rights[].value
cc-by (c) Fernández Dueñas, Víctor et al., 2017

# metadata.dc.source[].value
Articles publicats en revistes (Patologia i Terapèutica Experimental)

# metadata.dc.title[].value
Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease